Eurofins Scientific SEERFSF +2.60%81 Current Ratio is 1.09 as of Dec. 2025, which is 13% below its 10-year median of 1.26. GuruFocus rates ERFSF with a GF Score™ of 81/100 and a GF Value™ of $76.00 (Fairly Valued). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 75.81% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Eurofins Scientific SE's current ratio for the quarter that ended in Dec. 2025 was 1.09.
Eurofins Scientific SE has a current ratio of 1.09. It generally indicates good short-term financial strength.
The historical rank and industry rank for Eurofins Scientific SE's Current Ratio or its related term are showing as below:
ERFSF'
s Current Ratio Range Over the Past 10 Years
Min: 1.01 Med: 1.26 Max: 2.22
Current: 1.09
During the past 13 years, Eurofins Scientific SE's highest Current Ratio was 2.22. The lowest was 1.01. And the median was 1.26.
ERFSF's Current Ratio is ranked worse than 75.81% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs ERFSF: 1.09
Eurofins Scientific SE (OTCPK:ERFSF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Eurofins Scientific SE Current Ratio Related Terms
Eurofins Scientific SE Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Current Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Current Ratio of 1.09 as of Dec. 2025. This is 13% below median its historical median of 1.26. Over the past decade, Eurofins Scientific SE's Current Ratio has ranged from 1.01 to 2.22. According to the industry distribution chart, Eurofins Scientific SE ranks #163 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 75.8%.
Is Eurofins Scientific SE's Current Ratio too high?
Eurofins Scientific SE's current Current Ratio of 1.09 is 13% below median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 2.22. The Medical Diagnostics & Research industry median Current Ratio is 1.96. Eurofins Scientific SE's value of 1.09 is 44.4% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #163 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #163 out of 215 companies for Current Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median Current Ratio is 1.96. Eurofins Scientific SE's value of 1.09 is 44.4% below this benchmark. Historically, Eurofins Scientific SE's own Current Ratio has ranged from 1.01 to 2.22 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 1.96, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.96, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Current Ratio of 1.09 is 44.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Current Ratio is 1.09, which is 13% below median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $76.00, compared to a current price of $76.03 — trading 0% above its estimated fair value. The current Current Ratio is 1.09, which is 13% below median its 10-year median of 1.26 and 44.4% below the Medical Diagnostics & Research industry median of 1.96. Eurofins Scientific SE's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Current Ratio is 1.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $76.03 is trading 0% above its estimated GF Value™ of $76.00.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Current Ratio: 1.09 (13% below median its 10-year median of 1.26)
GF Value™: $76.00 vs. price of $76.03 (0% above fair value)
Industry Position: 44.4% below the Medical Diagnostics & Research median (#163 of 215)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
81GF Score
Get the complete analysis for ERFSF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
